Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
16 Results for "
BRAF inhibitor (Standard)
" in MedChemExpress (MCE) Product Catalog:
Products (16)
16 Results for "BRAF inhibitor (Standard)" in MCE Product Catalog:
Cat. No.: HY-10247R
CAS No.: 918505-61-0
Target:
Research Areas:
BRAF inhibitor (Standard) is the analytical standard of BRAF inhibitor (HY-10247). This product is intended for research and analytical applications. BRAF inhibitor (Compound P-0850) is a B-Raf inhibitor with anti-tumor activity .
Cat. No.: HY-15605R
CAS No.: 1269440-17-6
Synonyms: LGX818 (Standard)
Target:
Research Areas:
Encorafenib (Standard) is the analytical standard of Encorafenib. This product is intended for research and analytical applications. Encorafenib (LGX818) is a highly potent BRAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAF V600E (EC50=4 nM).
Cat. No.: HY-51424R
CAS No.: 918505-84-7
PLX-4720 (Standard) is the analytical standard of PLX-4720. This product is intended for research and analytical applications. PLX-4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf.
Cat. No.: HY-14660R
CAS No.: 1195765-45-7
Synonyms: GSK2118436A (Standard); GSK2118436 (Standard)
Target:
Research Areas:
Dabrafenib (Standard) is the analytical standard of Dabrafenib. This product is intended for research and analytical applications. Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC50s of 5 nM and 0.6 nM for C-Raf and B-Raf V600E, respectively .
Cat. No.: HY-10966R
CAS No.: 405554-55-4
Target:
Research Areas:
SB-590885 (Standard) is the analytical standard of SB-590885 (HY-10966). This product is intended for research and analytical applications. SB-590885 is a BRAF/c-Raf kinase inhibitor that selectively targets B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer .
Cat. No.: HY-12057R
CAS No.: 918504-65-1
Synonyms: PLX4032 (Standard); RG7204 (Standard); RO5185426 (Standard)
Target:
Research Areas:
Vemurafenib (Standard) is the analytical standard of Vemurafenib. This product is intended for research and analytical applications. Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAF V600E and c-RAF-1, respectively . Vemurafenib induces cell autophagy .
Cat. No.: HY-17598R
CAS No.: 22662-39-1
Rafoxanide (Standard) is the analytical standard of Rafoxanide. This product is intended for research and analytical applications. Rafoxanide is a poent, orally active halogenated salicylaniline agent with antiparasitic activity. Rafoxanide interferes with energy metabolism in trematodes by uncoupling oxidative phosphorylation. Rafoxanide is also found to be a potent inhibitor of the BRAF V600E mutant protein, which is important in colorectal cancer. Rafoxanide can be used for the control of infestation with Hemonchus species or Fasciola species in sheep and cattle as well as Oestrus ovis in sheep. Rafoxanide can also be used for cancer research .
Cat. No.: HY-10320R
CAS No.: 285983-48-4
Synonyms: BIRB 796 (Standard)
Target:
Research Areas:
Doramapimod (Standard) is the analytical standard of Doramapimod. This product is intended for research and analytical applications. Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (Kd=0.1 nM). Doramapimod also inhibits B-Raf with an IC50 of 83 nM .
Cat. No.: HY-111758R
CAS No.: 2364367-27-9
Target:
Research Areas:
PROTAC B-Raf degrader 1 (Standard) is the analytical standard of PROTAC B-Raf degrader 1 (HY-111758). This product is intended for research and analytical applications. PROTAC B-Raf degrader 1 is a PROTAC degrader targeting B-Raf, which recruits the ubiquitin-proteasome system to accelerate B-Raf degradation and reduce the expression of downstream Mcl-1. PROTAC B-Raf degrader 1 inhibits cancer cell proliferation, arrests cell cycle and induces apoptosis. PROTAC B-Raf degrader 1 can be used in breast cancer-related research .
Cat. No.: HY-107779R
CAS No.: 1392429-79-6
Target:
Research Areas:
BI-882370 (Standard) is the analytical standard of BI-882370 (HY-107779). This product is intended for research and analytical applications. BI-882370 is a potent and selective RAF Kinase inhibitor that binds to the ATP binding site of the Kinase positioned in the DFG-out (inactive) conformation of the BRAF Kinase. BI-882370 (BI 882370) inhibits the oncogenic BRAFV600E-mutant, the WT BRAF and CRAF Kinases with IC50s of 0.4, 0.8, and 0.6 nM, respectively. BI-882370 also inhibits SRC family Kinases .
Cat. No.: HY-100510R
CAS No.: 1628838-42-5
Target:
Research Areas:
RAF709 (Standard) is the analytical standard of RAF709 (HY-100510). This product is intended for research and analytical applications. RAF709 is a potent, selective, and efficacious RAF inhibitor with IC50s of 0.4 nM and 0.5 nM for BRAF and CRAF, respectively . Antitumor efficacy .
Cat. No.: HY-109080R
CAS No.: 1446113-23-0
Synonyms: HM95573 (Standard); GDC-5573 (Standard); RG6185 (Standard)
Target:
Research Areas:
Belvarafenib (Standard) is the analytical standard of Belvarafenib (HY-109080). This product is intended for research and analytical applications. Belvarafenib (HM95573) is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively .
Cat. No.: HY-11004R
CAS No.: 878739-06-1
Target:
Research Areas:
AZ 628 (Standard) is the analytical standard of AZ 628 (HY-11004). This product is intended for research and analytical applications. AZ 628 is a pan-Raf Kinase inhibitor with IC50s of 105, 34 and 29 nM for B-Raf, B-RafV600E, and c-Raf-1, respectively.
Cat. No.: HY-50846R
CAS No.: 942183-80-4
Target:
Research Areas:
SCH772984 (Standard) is the analytical standard of SCH772984 (HY-50846). This product is intended for research and analytical applications. SCH772984 is a highly selective and ATP-competitive ERK inhibitor, with IC50s of 4 and 1 nM for ERK1 and ERK2, respectively. SCH772984 has antitumor activity in MAPK inhibitor-naive and MAPK inhibitor-resistant cells containing BRAF or RAS mutations .
Cat. No.: HY-101494R
CAS No.: 1951483-29-6
Synonyms: LY3214996 (Standard)
Target:
Research Areas:
Temuterkib (Standard) is the analytical standard of Temuterkib (HY-101494). This product is intended for research and analytical applications. Temuterkib (LY3214996) is a highly selective inhibitor of ERK1 and ERK2, with IC50 of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. Temuterkib shows potent antitumor activities in cancer models with MAPK pathway alterations.
Cat. No.: HY-148439R
CAS No.: 2765081-21-6
Synonyms: RMC-6236 (Standard); RAS-IN-2 (Standard)
Target:
Research Areas:
Daraxonrasib (Standard) is the analytical standard of Daraxonrasib (HY-148439). This product is intended for research and analytical applications. Daraxonrasib (RMC-6236) is an orally active, non-covalent RAS (ON) inhibitor. Daraxonrasib disrupts the interaction of wild-type or mutant RAS proteins with the RAS binding domain of BRAF, with EC50 values ranging from 28-220 nM for wild-type KRAS, NRAS, HRAS, and multiple oncogenic RAS variants. Daraxonrasib inhibits pERK. Daraxonrasib has anti-tumor activity against KRAS mutant tumors .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
